|
|
|
市場調查報告書
生物製劑研發動向：下一個有希望的單株抗體
Biologics Pipelines: Who Has the Next Promising Monoclonal Antibodies?
|
生物製劑研發動向：下一個有希望的單株抗體 是由出版商Decision Resources, Inc.在2008年03月所出版的。
這份英文市場調查報告書包含39 Pages 價格從美金2250起跳。
本報告書內容為：生物製劑市場概要、10種藥物單株抗體研發動向、單株抗體市場動向、專家看法等等，內容綱要摘記如下：
摘要
生物製劑市場動向
阿茲海默症與抗Amyloid抗體
- Elan/Wyeth的AAB-001
- 針對阿茲海默症的早期臨床階段單株抗體
抗Integrin抗體
- Biogen Idec/Elan的Tysabri
- 早期臨床階段的抗Integrin抗體
- Biogen Idec/PDL Biopharma的M-200
- Johnson & Johson/Centocor/Medarex的CNTO-05
- Millennium的MLN-0002
T細胞副刺激拮抗劑
- 超作用藥物
- Bristol-Myers Squibb的Orencia
- 三種第三相藥劑
Complement與Complement Receptor抗體
- HIV抗體療法
- 阻止免疫細胞往發炎部位的移動
- 促進細胞毒性的CCR4抗體
B細胞標的療法：抗CD20抗體
- Biogen Idex/Genetech/中外製藥/全藥工業的Rituxan
- 臨床研發中的抗CD20抗體
- 下一代工程抗體
- 放射免疫治療
T細胞標的療法
新型Interleukin-6 Receptor拮抗藥物類別
腫瘤壞死因素Alpha阻礙劑
EGFR標的療法
- Bristol-Myers Squibb/Imclone Systems/Merck Serono的Erbitux
- Amgen的Vectibix
- 臨床研發中的EGFR拮抗藥
Abstract
Introduction
Monoclonal antibodies (MAbs) are very hot commodities in today' s
pharmaceutical marketplace, and in recent years, the growth in the number of
MAbs under development has far outpaced the growth of other types of drugs.
With expert insight from our Decision Resources analysts, we look at
approximately 70 MAbs in latestage development, identify promising MAbs, and
discuss four developing trends in MAb markets.
Get the Answers You Need to Shape Your Strategy
- Monoclonal antibodies are one of the fastest growing segments of the
pharmaceutical industry. Will the intense competition in this market lead
to saturation in some segments? Which classes could get crowded if new MAbs in
development successfully enter the market?
- MAbs are highly sought after by the pharmaceutical industry to fi ll
sparse pipelines with new biologics. Which companies are looking to ramp up
their MAb production? Who will be the key players in this arena going
forward?
- MAb markets are becoming complex, and companies with emerging MAbs need to
carefully consider how best to position their products. Which factors will
be the most important to ensuring market success for new MAbs? What strategies
are companies pursuing?
Scope
- A review of the evolving biologics market: the role of MAbs, sales
fi gures, market leaders.
- MAbs in development in ten different drug classes: their stage of
development and the companies developing them.
- Four interesting trends in MAb markets: developments that are
adding new layers of complexity to the MAb landscape, trends to be carefully
considered when entering or competing in today' s evolving MAb markets,
implications for stakeholders.
- Expert insight from Decision Resources analysts: comparison of the
relative merits of MAbs now in development, by the following analysts:
- Madhuri Borde, Ph.D., analyst, Immune and Infl ammatory Disorders
- Sylvia Eash, Ph.D., analyst, Infectious Disease
- Clair Gricks, Ph.D., analyst, Onkos
- Neil Grubert, M.A., director of pricing and reimbursement, Spectrum,
Pharmacoeconomics, Pricing, and Reimbursement
- Bethany A. Kiernan, Ph.D., analyst, Cognos
- Joanna Kim, M.Ed., analyst, Immune and Infl ammatory Disorders
- Nitasha Manchanda, Ph.D., analyst, Cognos
- Jennifer Moniz Carpenter, M.B.A., program manager, Spectrum, Therapy
Markets and Emerging Technologies
- Mohamed Muhsin, M.Sc., analyst, Onkos
- Alice von Loesecke, Ph.D., senior director, New Products
Table of Contents
- Executive Summary
- Strategic Considerations
- Trends and Their Implications for Stakeholders
- Evolving Biologics Market
- Alzheimer' s Disease and Anti-Amyloid Antibodies
- Elan/Wyeth' s AAB-001 (Bapineuzumab)
- MAbs in Early-Stage Clinical Development for Alzheimer' s Disease
- Anti-Integrin Antibodies
- Biogen Idec/Elan' s Tysabri (Natalizumab)
- Anti-Integrin Antibodies in Early-Stage Clinical Development
- Biogen Idec/PDL BioPharma' s M-200 (Volociximab)
- Johnson & Johnson/Centocor/Medarex' s CNTO-95
- Millennium' s MLN-0002
- Selective T-Cell Co-Stimulation Antagonists
- Superagonist Debacle
- Bristol-Myers Squibb' s Orencia (Abatacept)
- Three Phase III Contenders
- Bristol-Myers Squibb' s LEA29Y (Belatacept)
- Medarex/Bristol-Myers Squibb' s MDX-010 (Ipilimumab)
- Pfi zer' s CP-675,206 (Tremelimumab)
- Complement and Complement Receptor Antibodies
- HIV Antibody Therapies
- Blocking Immune Cell Migration to Infl ammation Sites
- Cytotoxicity-Enhanced CCR4 Antibody
- B-Cell-Targeted Therapies: Anti-CD20 Antibodies
- Biogen Idec/Genentech/Roche/Chugai/Zenyaku' s Rituxan/MabThera (Rituximab)
- Anti-CD20 Antibodies in Clinical Development
- Biogen Idec/Genentech/Roche' s R-1594/PRO-70769 (Ocrelizumab)
- GlaxoSmithKline/Genmab' s HuMax-CD20 (Ofatumumab)
- Immunomedics' IMMU-106 (Veltuzumab)
- Next-Generation Engineered Antibodies
- Radioimmunotherapy
- T-Cell-Targeted Therapies
- Anti-CD3 Antibodies
- Agents in Development for Recent-Onset Type 1 Diabetes
- Agents in Development for Infl ammatory Bowel Diseases
- CD4-Targeting Antibodies
- Novel Interleukin-6 Receptor Antagonist Class
- Tumor Necrosis Factor-Alpha Inhibitors
- EGFR-Targeted Therapies
- Bristol-Myers Squibb/ImClone Systems /Merck Serono' s Erbitux (Cetuximab)
- Amgen' s Vectibix (Panitumumab)
- EGFR Antagonists in Clinical Development
- Oncoscience/YM Bioscience/Daiichi Sankyo' s TheraCIM h-R3/Theraloc
(Nimotuzumab)
- Genmab' s HuMax-EGFR (Zalutumumab)
- Merck Serono/Takeda' s EMD-72000 (Matuzumab)
- Bristol-Myers Squibb/ImClone Systems' IMC-11F8
- Anti-VEGF Angiogenesis Inhibitors
- Genentech/Roche/Chugai' s Bevacizumab (Avastin)
- Drug Resistance and Combination Therapies
- Genentech/Novartis' s Lucentis (Ranibizumab)
- ThromboGenics/BioInvent' s TB-403
- Four Developing Trends
- Trend 1
- Trend 2
- Trend 3
- Trend 4
Tables:
- 1. Alzheimer' s Disease and Anti-Amyloid Antibodies
- 2. Anti-Integrin Antibodies
- 3. Selective T-Cell Co-Stimulation Antagonists
- 4. Select Complement Receptor Antibodies
- 5. Anti-CD20 Antibodies
- 6. Anti-CD3 Antibodies
- 7. Anti-CD4 Antibodies
- 8. Tumor Necrosis Factor Alpha (TNF-α) Antibodies
- 9. Anti-EGFR Antibodies
- 10. Anti-VEGF Angiogenesis Inhibitors
Figures:
- 1. Evolving Pharmaceutical Market Segments Based on Technology, 2000-2012
- 2. Top-Selling Monoclonal Antibodies, 2007
- 3. Amyloid Plaques and Neurofi brillary Tangles in Alzheimer' s Disease
- 4. Mechanisms of T-Cell Co-Stimulation
- 5. The Life Cycle of HIV-1
- 6. EGFR Family
- 7. The Angiogenic Process
- 8. TNF-Alpha Inhibitors, 2006-2016: Market Share
Decision Resources, Inc., Analysts Featured
- Madhuri Borde, Ph.D., analyst, Immune and Infl ammatory Disorders
- Sylvia Eash, Ph.D., analyst, Infectious Disease
- Clair Gricks, Ph.D., analyst, Onkos
- Neil Grubert, M.A., director of pricing and reimbursement, Spectrum,
Pharmacoeconomics, Pricing, and Reimbursement
- Bethany A. Kiernan, Ph.D., analyst, Cognos
- Joanna Kim, M.Ed., analyst, Immune and Infl ammatory Disorders
- Nitasha Manchanda, Ph.D., analyst, Cognos
- Jennifer Moniz Carpenter, M.B.A., program manager, Spectrum, Therapy
Markets and Emerging Technologies
- Mohamed Muhsin, M.Sc., analyst, Onkos
- Alice von Loesecke, Ph.D., senior director, New Products
|
 |
